(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Cataldo DM and Van Nest G | The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice. | 1997 | Vaccine | pmid:9364672 |
Barchfeld GL et al. | The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. | 1999 | Vaccine | pmid:10067675 |
Süli J et al. | Experimental squalene adjuvant. I. Preparation and testing of its effectiveness. | 2004 | Vaccine | pmid:15308373 |
Tritto E et al. | Mechanism of action of licensed vaccine adjuvants. | 2009 | Vaccine | pmid:19200813 |
Ansaldi F et al. | Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection. | 2009 | Vaccine | pmid:19200846 |
Okike IO et al. | The immunogenicity of a novel A (H1N1) vaccine in HIV-infected children. | 2011 | Vaccine | pmid:21742005 |
Ansaldi F et al. | Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. | 2008 | Vaccine | pmid:18294741 |
de Roux A et al. | Impact of corticosteroids on the immune response to a MF59-adjuvanted influenza vaccine in elderly COPD-patients. | 2006 | Vaccine | pmid:16288937 |
Reynales H et al. | A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. | 2012 | Vaccine | pmid:22902681 |
Puig-Barberà J et al. | MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system. | 2013 | Vaccine | pmid:23731629 |